Duff & Phelps Investment Management Co. acquired a new stake in shares of Novartis AG (NYSE:NVS) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 50,811 shares of the company’s stock, valued at approximately $4,360,000.
A number of other large investors also recently modified their holdings of NVS. Sonora Investment Management LLC lifted its stake in Novartis by 93.9% during the 4th quarter. Sonora Investment Management LLC now owns 479 shares of the company’s stock valued at $41,000 after acquiring an additional 232 shares in the last quarter. Cornerstone Advisors Inc. lifted its stake in Novartis by 89.4% during the 3rd quarter. Cornerstone Advisors Inc. now owns 502 shares of the company’s stock valued at $43,000 after acquiring an additional 237 shares in the last quarter. Lavaca Capital LLC bought a new position in Novartis during the 4th quarter valued at $48,000. Focused Wealth Management Inc raised its stake in shares of Novartis by 29.9% during the 4th quarter. Focused Wealth Management Inc now owns 868 shares of the company’s stock worth $74,000 after purchasing an additional 200 shares during the period. Finally, Stelac Advisory Services LLC bought a new stake in shares of Novartis during the 3rd quarter worth $113,000. Institutional investors and hedge funds own 11.18% of the company’s stock.
A number of equities research analysts have recently commented on the company. Zacks Investment Research upgraded Novartis from a “hold” rating to a “buy” rating and set a $96.00 target price on the stock in a research note on Tuesday, December 18th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novartis in a research note on Wednesday, November 28th. Jefferies Financial Group reiterated a “buy” rating and set a $105.00 target price on shares of Novartis in a research note on Tuesday, December 11th. Cowen upgraded Novartis from a “market perform” rating to an “outperform” rating and set a $88.03 target price on the stock in a research note on Sunday, December 2nd. Finally, Barclays cut Novartis from an “equal weight” rating to a “sell” rating in a research note on Friday, December 7th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Novartis currently has a consensus rating of “Hold” and a consensus target price of $90.94.
NYSE NVS opened at $88.85 on Friday. The firm has a market cap of $204.02 billion, a PE ratio of 17.46, a price-to-earnings-growth ratio of 1.92 and a beta of 0.69. Novartis AG has a one year low of $72.30 and a one year high of $92.39. The company has a current ratio of 1.20, a quick ratio of 0.97 and a debt-to-equity ratio of 0.29.
Novartis (NYSE:NVS) last released its earnings results on Wednesday, January 30th. The company reported $1.24 EPS for the quarter, missing the Zacks’ consensus estimate of $1.33 by ($0.09). The business had revenue of $13.27 billion for the quarter, compared to the consensus estimate of $13.33 billion. Novartis had a return on equity of 15.66% and a net margin of 24.30%. The company’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.21 earnings per share. As a group, sell-side analysts forecast that Novartis AG will post 5.43 EPS for the current fiscal year.
The company also recently disclosed an annual dividend, which will be paid on Wednesday, March 13th. Investors of record on Tuesday, March 5th will be issued a $2.8646 dividend. The ex-dividend date of this dividend is Monday, March 4th. This represents a yield of 3.27%. This is a positive change from Novartis’s previous annual dividend of $2.33. Novartis’s dividend payout ratio (DPR) is 37.52%.
TRADEMARK VIOLATION NOTICE: “Duff & Phelps Investment Management Co. Invests $4.36 Million in Novartis AG (NVS) Stock” was first posted by Macon Daily and is the sole property of of Macon Daily. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://macondaily.com/2019/02/09/duff-phelps-investment-management-co-invests-4-36-million-in-novartis-ag-nvs-stock.html.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.
Recommended Story: Trading signals using Bollinger bands
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.